Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies

Kiadis Pharma

Kiadis Pharma is a biopharmaceutical company that develops and commercializes T-cell based immunotherapies for the treatment of blood cancer. Read more

13 Followers on Owler
13 Followers on Owler
13 Followers on Owler
13 Followers on Owler

Kiadis Pharma

Kiadis Pharma is a biopharmaceutical company that develops and commercializes T-cell based immunotherapies for the treatment of blood cancer. Read more

Arthur Lahr's photo - CEO of Kiadis Pharma

CEO

Arthur Lahr

CEO Approval Rating

86/100

Founded:

1997

Status:

PublicAcquired by Sanofi S.ANYSE EuronextKDS

SIC Code:

8731 NAICS listing »

2834 NAICS listing »

Website:

Annual Revenue
Employees
Sector
Pharmaceuticals
Headquarters

KIADIS PHARMA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

The top 10 competitors in Kiadis Pharma's competitive set are Glycostem, NexImmune, Phio Pharmaceuticals, CytImmune, Kite Pharma, TILT Biotherapeutics, Lava Therapeutics, DCprime B.V., TC Biopharm, Endocyte. Together they have raised over 3.1B between their estimated 3.7K employees. Kiadis Pharma has 170 employees and is ranked 4th among it's top 10 competitors. The top 10 competitors average 168.

Glycostem is one of Kiadis Pharma's top rivals. Glycostem's headquarters is in Oss, Noord-Brabant, and was founded in 2007. Like Kiadis Pharma, Glycostem also competes in the Pharmaceuticals industry. Glycostem generates ∞% of Kiadis Pharma's revenue.

NexImmune has been one of Kiadis Pharma's top competitors. NexImmune was founded in 2011 in Gaithersburg, Maryland. Like Kiadis Pharma, NexImmune also operates in the Pharmaceuticals field. NexImmune generates $ less revenue than Kiadis Pharma.

Phio Pharmaceuticals is one of Kiadis Pharma's top competitors. Phio Pharmaceuticals was founded in Marlborough, Massachusetts} in 2011. Like Kiadis Pharma, Phio Pharmaceuticals also competes in the Pharmaceuticals sector. Compared to Kiadis Pharma, Phio Pharmaceuticals generates $21K more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Kite Pharma a competitor of Kiadis Pharma?

I don't know

Kiadis Pharma Quarterly and Annual Revenue

Coming soon for Kiadis Pharma!

Annual Revenue

Kiadis Pharma Acquisitions

No recent acquisitions found related to Kiadis Pharma

Kiadis Pharma Funding History

Since Kiadis Pharma was founded in 1997, it has participated in 9 rounds of funding. In total Kiadis Pharma has raised $187.8M. Kiadis Pharma's last funding round was on Apr 2020 for a total of $5.4M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Apr 2020
$5.4M
-
Private Placement
Apr 2020
$13M
-
Private Placement
May 2019
$30.7M
-
Private Placement
Oct 2018
$35.8M
-
Debt
Jul 2018
$23.4M

Total Funding: $187.8M

Since Kiadis Pharma was founded in 1997, it has participated in 9 rounds of funding. In total Kiadis Pharma has raised $187.8M. Kiadis Pharma's last funding round was on Apr 2020 for a total of $5.4M

Kiadis Pharma Investments

No recent investments found related to Kiadis Pharma

Kiadis Pharma News

April 7, 2021Benzinga

Kiadis Pharma announces annual results for the year ended December 31, 2020

New strategic focus results in significant progress in cell based therapies Amsterdam, The Netherland... See more »
March 30, 2021MarketScreener

EGM Presentation

(marketscreener.com) Disclaimer These slides and the accompanying oral presentation contain forward-l... See more »
March 9, 2021MarketScreener

Corporate Presentation March 2021

(marketscreener.com) KIADIS PHARMA | COMPANY PRESENTATION | MARCH 2021 EURONEXT: KDS Leveraging the n... See more »
February 13, 2021MarketScreener

EGM 2021 Q&A Protocol

(marketscreener.com) Appendix I - EGM Q&A Protocol PROTOCOL FOR ASKING QUESTIONS BEFORE AND DURING TH... See more »
February 12, 2021Markets Insider

Sanofi Launches Recommended Cash Offer For Kiadis

(RTTNews) - Sanofi (SNY) said it has made an recommended all-cash offer to all the shareholders to ac... See more »
February 12, 2021MarketScreener

AFM Certificate of Approval 2nd Supplement February 2021

(marketscreener.com) Certificate of Approval of a Supplement pursuant to Prospectus Regulation 2017/1... See more »
February 12, 2021CompanyNews HQ

Offer Memorandum for All Outstanding Shares of Kiadis Pharma N.V.

View post on CompanyNewsHQ: Offer Memorandum for All Outstanding Shares of Kiadis Pharma N.V.... See more »

Kiadis Pharma Press Releases

February 2, 2021GlobalNewswire

Kiadis Shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi

This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the... See more »
December 9, 2020StreetInsider

Sanofi and Kiadis satisfy competition condition related to the tender offer

See more »
June 25, 2020GlobeNewswire

Kiadis Announces Results of Annual General Meeting of Shareholders

Amsterdam, The Netherlands, June 25, 2020 - Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext ... See more »
May 14, 2020GlobeNewswire

Kiadis Pharma kondigt meerdere presentaties over het K-NK-celtherapieplatform voor 25e congres van European Hematology Association

Amsterdam, 14 mei 2020 - Kiadis Pharma NV ("Kiadis Pharma" of de "Onderneming") (Euronext Amsterdam e... See more »
May 13, 2020GlobeNewswire

Oproep voor de Algemene Vergadering van Aandeelhouders

Amsterdam, 13 mei 2020 - Kiadis Pharma N.V. ("Kiadis Pharma" of de "Vennootschap") (Euronext Amsterda... See more »
May 13, 2020StreetInsider

Notice of Annual General Meeting of Shareholders

Amsterdam, The Netherlands, 13 May 2020 Kiadis Pharma N.V. (Kiadis Pharma or the Company) (Euronext ... See more »
April 28, 2020GlobeNewswire

Kiadis Pharma haalt 12 miljoen financiering op door onderhandse plaatsing van aandelen bij een Amerikaanse biotech investeerder

THIS PRESS RELEASE AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR PUBLIC RELEASE, PUB... See more »

Social Media

Kiadis Pharma Headquarters

Paasheuvelweg 25A

Amsterdam, Zuid-Holland1105

31-20-240-52-50

Driving Directions »

Trending Companies

Kiadis Pharma Summary

ABOUT

Overview

Kiadis Pharma is a biopharmaceutical company that develops and commercializes T-cell based immunotherapies for the treatment of blood cancer. Kiadis Pharma was founded in 1997. Kiadis Pharma's headquarters is located in Amsterdam, Zuid-Holland, NL 110...

CEO

Kiadis Pharma's CEO, Arthur Lahr, currently has an approval rating of 86%. Kiadis Pharma's primary competitors are Glycostem, NexImmune & Phio Pharmaceuticals.

Website

kiadis.com

Frequently Asked Questions about Kiadis Pharma

  1. When was Kiadis Pharma founded?

    Kiadis Pharma was founded in 1997

  2. Who is Kiadis Pharma's CEO?

    Kiadis Pharma's CEO is Arthur Lahr

  3. How much revenue does Kiadis Pharma generate?

    Kiadis Pharma generates $ < 1M in revenue

  4. How much funding does Kiadis Pharma have?

    Kiadis Pharma has historically raised $187.8M in funding

  1. Where is Kiadis Pharma's headquarters?

    Kiadis Pharma's headquarters is in Amsterdam Zuid-Holland, NL

  2. How many employees does Kiadis Pharma have?

    Kiadis Pharma has 170 employees

  3. What sector does Kiadis Pharma operate in?

    Kiadis Pharma is in Pharmaceuticals

  4. Who are Kiadis Pharma's competitors?

    Kiadis Pharma's top competitors are Glycostem, NexImmune, Phio Pharmaceuticals
Stay up-to-date with the latest news on Kiadis Pharma

© 2021 Owler, Inc.